Keywords: positive, ph, iii, data, ista, xibrom, usa-based
Positive Ph III data for ISTA's Xibrom
Article | 15 March 2004
USA-based ISTA Pharmaceuticals has reported positive preliminary findings from Phase III trials of its Xibrom (0.1% bromfenac sodium ophthalmic solution), a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
